Liver Meeting® 2018 - Fatty Liver Disease in the Spotlight

Friday, November 2, 2018

Liver Meeting® 2018 - Fatty Liver Disease in the Spotlight

AASLD 2018
San Francisco, CA. November 9-13, 2018.

Medscape Medical News, November 2, 2018

Fatty Liver Disease in the Spotlight at The Liver Meeting

Current and future treatments for fatty liver disease, particularly nonalcoholic steatohepatitis, the most prevalent liver disease in the United States, will be explored at The Liver Meeting....

Results from phase 2 studies of drugs for nonalcoholic steatohepatitis — Mgl-3196 (Madrigal Pharmaceuticals), obeticholic acid (Ocaliva/Intercept Pharmaceuticals), GS-9674 (Gilead Sciences), NGM282 (NGM Bio), arachidyl amido cholanoic acid (Aramchol, Galmed Pharmaceuticals), and tropifexor (Novartis) — will be presented.

Researchers are figuring out how to make better use of the treatments they have on hand, particularly for hepatitis C and hepatocellular carcinoma, said Kimberly Brown, MD, from the Henry Ford Health System in Detroit, who is cochair of the scientific programming committee for the meeting....

Read More.....

Recommended Reading

NAFLD Is a Growing Problem

Medscape Gastroenterology, May 18, 2018

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.